Gregory; Susan A

Patent Applications and Registrations

Patent applications and USPTO patent grants for Gregory; Susan A.The latest application filed is for "immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor".

Company Profile

0.13.5

Gregory; Susan A - St. Louis MO
Gregory; Susan A. - St. Louis MO
Gregory, Susan A. - San Diego CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B.sub.4 receptor inhibitor and a cyclosporin Grant 7,141,599 - Gregory , et al. November 28, 2	2006-11-28
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor Grant 7,132,441 - Gregory , et al. November 7, 2	2006-11-07
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor App 20050043355 - Gregory, Susan A. ; et al.	2005-02-24
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin App 20040106668 - Gregory, Susan A. ; et al.	2004-06-03
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin Grant 6,617,345 - Gregory , et al. September 9, 2	2003-09-09
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor App 20030004191 - Gregory, Susan A. ; et al.	2003-01-02
Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor App 20020143033 - Gregory, Susan A. ; et al.	2002-10-03
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist App 20020107276 - Isakson, Peter C. ; et al.	2002-08-08
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor Grant 6,407,140 - Gregory , et al. June 18, 2	2002-06-18
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist Grant 6,342,510 - Isakson , et al. January 29, 2	2002-01-29
Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives Grant 6,265,439 - Mueller , et al. July 24, 2	2001-07-24
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist Grant 6,172,096 - Gregory , et al. January 9, 2	2001-01-09
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor Grant 6,136,839 - Isakson , et al. October 24, 2	2000-10-24
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A.sub.4 hydrolase inhibitor Grant 5,990,148 - Isakson , et al. November 23, 1	1999-11-23
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A.sub.4 hydrolase inhibitor Grant 5,700,816 - Isakson , et al. December 23, 1	1997-12-23
Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives Grant 5,451,604 - Mueller , et al. September 19, 1	1995-09-19
Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives Grant 5,247,119 - Fowler , et al. September 21, 1	1993-09-21
Substantially pure cytotoxicity triggering factor Grant 4,785,077 - Kornbluth , et al. November 15, 1	1988-11-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.